

United States  
Environmental Protection  
Agency


Air and Radiation  
(6601J)

EPA 402-R-99-001  
September 1999



# **Cancer Risk Coefficients for Environmental Exposure to Radionuclides**

**Federal Guidance Report No. 13**



This report was prepared as an account of work sponsored by agencies of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof.

An electronic document version of this report is available at the US EPA world-wide-web site: <http://www.epa.gov/radiation/federal>. Additional Federal Guidance related information and reports are also available at this site.

This report was prepared for the  
Office of Radiation and Indoor Air  
U.S. Environmental Protection Agency  
Washington, DC 20460  
by  
Oak Ridge National Laboratory  
Oak Ridge, Tennessee 37831

**Federal Guidance Report No. 13**

**Cancer Risk Coefficients for  
Environmental Exposure  
to Radionuclides**

**Radionuclide-Specific Lifetime Radiogenic Cancer  
Risk Coefficients for the U.S. Population, Based on  
Age-Dependent Intake, Dosimetry, and Risk Models**

**Keith F. Eckerman  
Richard W. Leggett  
Christopher B. Nelson  
Jerome S. Puskin  
Allan C. B. Richardson**

**Oak Ridge National Laboratory  
Oak Ridge, Tennessee 37831**

**Office of Radiation and Indoor Air  
United States Environmental Protection Agency  
Washington, DC 20460**

**September 1999**

## PREFACE

The Federal Radiation Council (FRC) was formed in 1959, through Executive Order 10831. A decade later its functions were transferred to the Administrator of the newly formed Environmental Protection Agency (EPA) as part of Reorganization Plan No. 3 of 1970. Under these authorities it is the responsibility of the Administrator to "advise the President with respect to radiation matters, directly or indirectly affecting health, including guidance for all Federal agencies in the formulation of radiation standards and in the establishment and execution of programs of cooperation with States." The purpose of this guidance to Federal Agencies is to ensure that the regulation of exposure to ionizing radiation is adequately protective, reflects the best available scientific information, and is carried out in a consistent manner.

Since the mid-1980s, EPA has issued a series of Federal guidance documents for the purpose of providing the Federal and State agencies technical information to assist their implementation of radiation protection programs. The first report in this series, Federal Guidance Report No. 10 (EPA, 1984a), presented derived concentrations of radioactivity in air and water corresponding to the limiting annual doses recommended for workers in 1960. That report was superseded in 1988 by Federal Guidance Report No. 11 (EPA, 1988), which provided updated dose coefficients for internal exposure of members of the general public and limiting values of radionuclide intake and air concentrations for implementation of the 1987 Radiation Protection Guidance for Occupational Exposure (EPA, 1987). Federal Guidance Report No. 12 (EPA, 1993) tabulated dose coefficients for external exposure to radionuclides in air, water, and soil.

This report, *Cancer Risk Coefficients for Environmental Exposure to Radionuclides, Federal Guidance Report No. 13*, provides numerical factors for use in estimating the risk of cancer from low-level exposure to radionuclides. A risk coefficient for a radionuclide that exposes persons through a given environmental medium is an estimate of the probability of radiogenic cancer mortality or morbidity per unit activity inhaled or ingested, for internal exposure, or per unit time-integrated activity concentration in air or soil, for external exposure. A risk coefficient may be interpreted either as the average risk per unit exposure for persons exposed throughout life to a constant activity concentration of a radionuclide in an environmental medium, or as the average risk per unit exposure for persons exposed for a brief period to the radionuclide in an environmental medium. The risk coefficients given in this document apply to populations that approximate the age, gender, and mortality experience characterized by the 1989-91 U.S. decennial life tables. These

coefficients are tabulated using the SI unit of activity (becquerel), as are the dose coefficients in Federal Guidance Report No. 11 and Report No. 12.

An interim version of this report was published for public comment in January 1998. That version described the methodology used for derivation of a risk coefficient and provided risk coefficients for exposure to any of approximately 100 important radionuclides through various environmental media. This final version includes the background information given in the interim version, extends the tabulation of risk coefficients to more than 800 radionuclides, and provides additional discussion of the sources and extent of uncertainty in estimates of cancer risk from exposure to radionuclides.

The tabulated risk coefficients are based on state-of-the-art methods and models that take into account age and gender dependence of intake, metabolism, dosimetry, radiogenic risk, and competing causes of death in estimating the risks to health from internal or external exposure to radionuclides. Although many of the biokinetic and dosimetric models used here are updates of models used in Federal Guidance Report No. 11, the present report does not replace either that document or Federal Guidance Report No. 12 or affect their use for radiation protection purposes. The dose coefficients given in Federal Guidance Report No. 11 and Report No. 12 continue to be recommended for determining conformance with the radiation protection guidance to Federal agencies issued by the President and will be updated in the future as warranted. The risk coefficients tabulated in the present report have a different purpose — they are intended for use in assessing risks from radionuclide exposure, in a variety of applications ranging from analyses of specific sites to the general analyses that support rule making. Although the application of these risk coefficients for purposes such as cost/benefit analysis, environmental impact statements (EISs), and environmental assessments (EAs) — especially by Federal agencies — is encouraged to promote consistency in risk assessment, such use is discretionary.

The tabulated risk coefficients are intended mainly for prospective assessments of potential cancer risks from long-term exposure to radionuclides in environmental media. While it is recognized that the tabulations are also likely to be used in retrospective analyses of radiation exposures of populations, it is emphasized that such analyses should be limited to estimation of total or average risks in large populations. The risk coefficients are not intended for application to specific individuals, ages, or genders and should not be used for that purpose. Also, the coefficients are based on radiation risk models developed for application either to low acute doses or low dose rates and should not be applied to accident cases involving high doses and dose rates, either in prospective or retrospective analyses.

Some risk assessment procedures are established as a matter of policy, and additional guidance may be needed before using these risk coefficients in such policy matters. For example, EPA recommends that radiation risk assessments for sites on the National Priorities List under the Comprehensive Environmental Response, Compensation, and Liability Act be performed using the Health Effects Assessment Summary Tables (HEAST), which are periodically updated to reflect new information, such as that contained in this report.

In using Federal Guidance Report No. 13, the cancer risk associated with a radionuclide intake or external exposure is calculated as the product of the appropriate cancer risk coefficient and the corresponding radionuclide intake or exposure. This calculation presumes that risk is directly proportional to intake or exposure, i.e., it follows a linear, no-threshold (LNT) model. Current scientific evidence does not rule out the possibility that the calculated risk at environmental exposure levels may be overestimates or underestimates. However, several recent expert panels (UNSCEAR, 1993, 1994; NRPB, 1993; NCRP, 1997) have concluded that the LNT model is sufficiently consistent with current information on carcinogenic effects of radiation that its use is scientifically justifiable for purposes of estimating risks from low doses of radiation. As a practical matter, the LNT approach is universally used for assessing the risk from environmental exposure to radionuclides as well as other carcinogens. Within the LNT context, sources of uncertainty in the radionuclide cancer risk coefficients are discussed in the report, and judgments of uncertainty in the risk coefficients are given in Chapter 2 for a number of radionuclides. As new scientific evidence becomes available, we shall consider its effect on the information presented in this report and shall update the report as needed.

The risk coefficients were calculated using the DCAL (Dose and Risk Calculation) software, developed at Oak Ridge National Laboratory for the EPA. DCAL is a comprehensive system for calculating dose and risk coefficients using age-dependent models. A manual describing the DCAL software and the quality assurance procedures for this software will be published separately.

This report would not have been possible without the contributions of the many investigators who produced the building blocks that provided the basis for the results presented here. These include: Jerome S. Puskin and Christopher B. Nelson, who assembled the models for age-dependent, organ-specific cancer risks; Richard W. Leggett and Keith F. Eckerman, who developed many of the age-specific biokinetic and dosimetric models published by the International Commission on Radiological Protection and who provided the basis for calculation of doses from internal and external exposure; and Robert Armstrong, who supplied pre-publication values for the 1989-91 U.S. decennial life tables. The major effort required to prepare the report itself was carried out by Keith F. Eckerman, Richard W. Leggett, Christopher B. Nelson, Jerome S. Puskin, and Allan C.B.

Richardson. Preparation of the report was funded by the U.S. Environmental Protection Agency, the U.S. Department of Energy (DOE), and the U.S. Nuclear Regulatory Commission (NRC).

Technical reviews for the draft interim version of the report were contributed by William J. Bair, Bernd Kahn, Charles E. Land, John R. Mauro, and Alan Phipps. Review comments on the interim version (EPA, 1998) were provided by Federal agencies (including NRC and DOE); State agencies, and members of the public. The EPA Science Advisory Board (SAB) formally reviewed and commented on the interim report. This final version of Federal Guidance Report No. 13 reflects consideration of all these comments.

We gratefully acknowledge the work of the authors, the agencies that contributed funding for this work, and the helpful comments of the technical reviewers, the Science Advisory Board, and the public. We would appreciate notice of any errors or suggestions for improvements so that they may be taken into account in future editions. You may address comments to Michael A. Boyd, Radiation Protection Division (6608J), U.S. Environmental Protection Agency, Washington, DC 20460.

Stephen D. Page, Director  
Office of Radiation and Indoor Air

## CONTENTS

<b>PREFACE</b> .....	iii
<b>LIST OF TABLES</b> .....	xi
<b>LIST OF FIGURES</b> .....	xiii
<b>CHAPTER 1. INTRODUCTION</b> .....	1
Radionuclides and exposure scenarios addressed .....	2
Applicability to the current U.S. population .....	3
Computation of the risk coefficients for internal exposure .....	4
1. Lifetime risk per unit absorbed dose at each age .....	4
2. Absorbed dose rates as a function of time post acute intake at each age .....	5
3. Lifetime cancer risk per unit intake at each age .....	6
4. Lifetime cancer risk for chronic intake .....	6
5. Average lifetime cancer risk per unit activity intake .....	7
Computation of the risk coefficients for external exposure .....	7
How to apply a risk coefficient .....	8
Limitations on use of the risk coefficients .....	9
Uncertainties associated with risk coefficients .....	10
Software used to compute the risk coefficients .....	12
Organization of the report .....	13
<b>CHAPTER 2. TABULATIONS OF RISK COEFFICIENTS</b> .....	15
Risk coefficients for inhalation .....	16
Risk coefficients for ingestion .....	17
Risk coefficients for external exposure .....	18
Adjustments for current age and gender distributions in the U.S. ....	19
<b>CHAPTER 3. EXPOSURE SCENARIOS</b> .....	137
Characteristics of the exposed population .....	137
Growth of decay chain members .....	137
Inhalation of radionuclides .....	138
Intake of radionuclides in food .....	141
Intake of radionuclides in tap water .....	142
External exposure to radionuclides in air .....	143
External exposure to radionuclides in soil .....	143
<b>CHAPTER 4. BIOKINETIC MODELS FOR RADIONUCLIDES</b> .....	145
The model of the respiratory tract .....	145
The model of the gastrointestinal tract .....	147



Systemic biokinetic models .....	151
Treatment of decay chain members formed in the body .....	155
Solution of the biokinetic models .....	156
<b>CHAPTER 5. DOSIMETRIC MODELS FOR INTERNAL EMITTERS .....</b>	<b>157</b>
Age-dependent masses of source and target regions .....	157
Dosimetric quantities .....	160
Nuclear decay data .....	161
Specific absorbed fractions for photons .....	161
Absorbed fractions for beta particles and discrete electrons .....	163
Absorbed fractions for alpha particles and recoil nuclei .....	164
Spontaneous fission .....	165
Computation of <i>SE</i> .....	165
<b>CHAPTER 6. DOSIMETRIC MODELS FOR EXTERNAL EXPOSURES .....</b>	<b>167</b>
Interpretation of dose coefficients from Federal Guidance Report No. 12 .....	167
Nuclear data files used .....	168
Radiations considered .....	169
Effects of indoor residence .....	170
<b>CHAPTER 7. RADIOGENIC CANCER RISK MODELS .....</b>	<b>171</b>
Types of risk projection models .....	171
Epidemiological studies used in the development of risk models .....	173
Modification of epidemiological data for application to low doses and dose rates ....	173
Relative biological effectiveness factors for alpha particles .....	174
Risk model coefficients for specific organs .....	174
Association of cancer type with dose location .....	178
Relation between cancer mortality and morbidity .....	180
Treatment of discontinuities in risk model coefficients .....	183
Computation of radionuclide risk coefficients .....	183
<b>APPENDIX A. MODELS FOR MORTALITY RATES</b>	
<b>FOR ALL CAUSES AND FOR SPECIFIC CANCERS .....</b>	<b>A-1</b>
<b>APPENDIX B. ADDITIONAL DETAILS OF THE DOSIMETRIC MODELS .....</b>	<b>B-1</b>
Definitions of special source and target regions .....	B-1
Age-dependent masses of source and target regions .....	B-2
Absorbed fractions for radiosensitive tissues in bone .....	B-2
<b>APPENDIX C. AN ILLUSTRATION OF THE MODELS AND METHODS USED</b>	
<b>TO CALCULATE RISK COEFFICIENTS FOR INTERNAL EXPOSURE ....</b>	<b>C-1</b>
Gastrointestinal tract model and $f_i$ values .....	C-1
Respiratory tract model .....	C-2

Biokinetics of absorbed thorium .....	C-4
Structure of the systemic biokinetic model for thorium .....	C-4
Parameter values for the systemic model for thorium .....	C-6
Predicted differences with age in the systemic biokinetics of thorium .....	C-8
Treatment of $^{232}\text{Th}$ chain members produced in systemic tissues .....	C-9
Comparison of updated and previous systemic models for thorium .....	C-11
Conversion of activity to estimates of dose rates to tissues .....	C-13
SE values .....	C-13
Use of SE values to calculate dose rates .....	C-16
Conversion of dose rates to estimates of radiogenic cancers .....	C-18
Comparison with risk estimates based on effective dose .....	C-22

#### **APPENDIX D: UNCERTAINTIES IN ESTIMATES OF CANCER RISK FROM ENVIRONMENTAL EXPOSURE TO RADIONUCLIDES .....**

Purposes of this appendix .....	D-1
General sources of uncertainty in biokinetic estimates .....	D-2
Uncertainties associated with the structure of a biokinetic model .....	D-2
Types of information used to construct biokinetic models for elements .....	D-2
Sources of uncertainty in applications of human data .....	D-3
Uncertainty in interspecies extrapolation of biokinetic data .....	D-4
Uncertainty in inter-element extrapolation of biokinetic data .....	D-6
Uncertainty in central estimates stemming from variability in the population .....	D-7
Examples of data sources for some specific biokinetic models .....	D-7
Model of the respiratory tract .....	D-7
Gastrointestinal tract model and $f_1$ values .....	D-9
Systemic biokinetic models for parent radionuclides .....	D-10
Models for radionuclides produced in the body by radioactive decay .....	D-17
Uncertainties in internal dosimetric models .....	D-18
Specific energy (SE) for photons .....	D-18
SEs for beta particles and discrete electrons .....	D-19
SEs for alpha particles .....	D-20
Special dosimetric problems presented by walled organs .....	D-21
Uncertainties in external dosimetric models .....	D-21
Transport of radiation from the environmental source to humans .....	D-21
Effects of age and gender .....	D-23
Uncertainties in risk model coefficients .....	D-24
Sampling variability .....	D-24
Diagnostic misclassification .....	D-24
Errors in dosimetry .....	D-25
Uncertainties in the effects of radiation at low dose and dose rate .....	D-26
Uncertainties in the RBE for alpha particles .....	D-29
Uncertainties in transporting risk estimates across populations .....	D-30
Uncertainties in age and time dependence of risk per unit dose .....	D-32

Uncertainties in site-specific cancer morbidity risk estimates .....	D-33
Imprecision in risk model coefficients as indicated by differences in expert judgments .....	D-33
Proposed procedure for assigning nominal uncertainty intervals to risk coefficients	D-34

<b>APPENDIX E. ADJUSTMENT OF RISK COEFFICIENTS FOR SHORT-TERM EXPOSURE OF THE CURRENT U.S. POPULATION .....</b>	<b>E-1</b>
Computation of risk coefficients for the hypothetical current population .....	E-1
Comparison of coefficients for the current and stationary populations .....	E-4

<b>APPENDIX F. SAMPLE CALCULATIONS .....</b>	<b>F-1</b>
--	------------

<b>APPENDIX G. NUCLEAR DECAY DATA .....</b>	<b>G-1</b>
---	------------

<b>GLOSSARY .....</b>	<b>GL-1</b>
-----------------------	-------------

<b>REFERENCES .....</b>	<b>R-1</b>
-------------------------	------------

## LIST OF TABLES

Table	Page
2.1	Mortality and morbidity risk coefficients for inhalation ..... 21
2.2a	Mortality and morbidity risk coefficients for ingestion of tap water and food ..... 83
2.2b	Mortality and morbidity risk coefficients for ingestion of iodine in food, based on usage of cow's milk ..... 105
2.3	Mortality and morbidity risk coefficients for external exposure from environmental media ..... 107
2.4	Uncertainty categories for selected risk coefficients ..... 129
3.1	Age- and gender-specific usage rates of environmental media, for selected ages .... 139
4.1	Absorption types considered in ICRP Publication 72 for particulate aerosols ..... 148
5.1	Source and target organs used in internal dosimetry methodology ..... 158
7.1	Revised mortality risk model coefficients for cancers other than leukemia, based on the EPA radiation risk methodology ..... 175
7.2	Revised mortality risk model coefficients for leukemia, based on the EPA radiation risk methodology ..... 176
7.3	Age-averaged site-specific cancer mortality risk estimates (cancer deaths per person-Gy) from low-dose, low-LET uniform irradiation of the body ..... 179
7.4	Dose regions associated with cancer types ..... 180
7.5	Lethality data for cancers by site in adults ..... 181
7.6	Age-averaged site-specific cancer morbidity risk estimates (cancer cases per person-Gy) from low-dose, low-LET uniform irradiation of the body ..... 182
A.1	Gender- and age-specific values for the survival function, $S(x)$ , and the expected remaining lifetime, $e^0(x)$ , used in this report ..... A-2
B.1	Age-specific masses of source and target organs ..... B-3
B.2	Absorbed fractions for alpha and beta emitters in bone ..... B-4
C.1	Age-specific transfer coefficients in the systemic biokinetic model for thorium ..... C-7
C.2	Predictions of 50-y integrated activity of $^{232}\text{Th}$ following injection into blood at age 100 d, 10 y, or 25 y ..... C-9
C.3	Comparison of estimated 50-y integrated activities of $^{232}\text{Th}$ and its decay chain members, assuming independent or shared kinetics of decay chain members, for the case of injection of $^{232}\text{Th}$ into blood of an adult ..... C-12
C.4	Comparison of ICRP's updated and previous models as predictors of 50-y integrated activity after acute intake of $^{232}\text{Th}$ by an adult ..... C-15
C.5	Comparison of cancer mortality risk coefficients with risk estimates based on effective dose, for ingestion or inhalation of $^{232}\text{Th}$ ..... C-24
D.1	Summary of reported data on uptake and retention of iodine by the human thyroid D-14
D.2	Age-averaged site-specific cancer morbidity risk estimates (cancer cases per person-Gy $\times 10^{-2}$ ) from low-LET uniform irradiation of the body at high dose and dose rate, as estimated by nine experts on health effects of radiation .. D-34

## LIST OF TABLES, continued

Table	Page
E.1 Average daily usage of environmental media by the two hypothetical populations ...	E-3
E.2 Comparison of risk coefficients for the two hypothetical populations .....	E-5
G.1 Summary information on the nuclear transformation of radionuclides .....	G-5

## LIST OF FIGURES

Figure	Page
1.1	Components of the risk coefficient computation . . . . . 4
3.1	Gender-specific survival functions for the stationary population . . . . . 138
3.2	Age- and gender-specific usage rates used to derive risk coefficients for inhalation, ingestion of water, ingestion of food (energy intake), and ingestion of milk . . 140
4.1	Structure of the ICRP's respiratory tract model . . . . . 146
4.2	Model of transit of material through the gastrointestinal tract . . . . . 149
4.3	Structure of the ICRP's biokinetic model for zirconium . . . . . 152
4.4	Structure of the ICRP's biokinetic model for iodine. . . . . 153
4.5	Structure of the ICRP's biokinetic model for iron . . . . . 154
4.6	The ICRP's generic model structure for calcium-like elements . . . . . 155
5.1	Illustration of phantoms used to derive age-dependent specific absorbed fractions for photons . . . . . 162
C.1	Predictions of the ICRP's updated and previous respiratory tract models, for inhalation of $^{232}\text{Th}$ in soluble, moderately soluble, or insoluble 1- $\mu\text{m}$ (AMAD) particles . . . . . C-3
C.2	The ICRP's generic framework for modeling the systemic biokinetics of a class of bone-surface-seeking elements, including thorium . . . . . C-5
C.3	Retention of $^{232}\text{Th}$ on trabecular surfaces for three ages at injection, as predicted by the updated model for thorium . . . . . C-8
C.4	Biokinetic model for thorium given in ICRP Publication 30 . . . . . C-12
C.5	Comparison of predictions of ICRP's updated and previous systemic biokinetic models for thorium . . . . . C-14
C.6	Age-specific $SE$ values (high-LET) for $^{232}\text{Th}$ . . . . . C-15
C.7	Estimated weight of red marrow as a function of age . . . . . C-16
C.8	Contributions of $^{232}\text{Th}$ in Trabecular Bone Surface, Trabecular Bone Volume, and Red Marrow to the high-LET dose rate to Red Marrow in the adult . . . . . C-17
C.9	Estimated dose rates to Red Marrow following acute ingestion of $^{232}\text{Th}$ , for three ages at ingestion . . . . . C-17
C.10	Estimated dose rates to Red Marrow following acute inhalation of moderately soluble $^{232}\text{Th}$ , for three ages at inhalation . . . . . C-17
C.11	Relative risk functions, $\eta(u, x)$ , for leukemia in males for three ages at irradiation . . C-19
C.12	Age- and gender-specific mortality rates for leukemia, based on U.S. data for 1989-91 . . . . . C-19
C.13	Gender-specific survival functions based on U.S. life tables for 1989-91 . . . . . C-20
C.14	Gender-specific lifetime risk coefficient ( $LRC$ ) functions for radiogenic leukemia . . C-20
C.15	Derived gender-specific risk $r_a(x_i)$ of dying from leukemia due to ingestion of 1 Bq of $^{232}\text{Th}$ in food at age $x_i$ . . . . . C-21

# LIST OF FIGURES, continued

Figure	Page
C.16 Derived gender-specific risk $r_a(x_i)$ of dying from leukemia due to inhalation of 1 Bq of $^{232}\text{Th}$ (Type M) at age $x_i$ .....	C-21
C.17 Gender-weighted average lifetime risk coefficients for ingestion of $^{232}\text{Th}$ in food, using updated and previous biokinetic models for thorium .....	C-22
C.18 Gender-weighted average lifetime risk coefficients for inhalation of moderately soluble $^{232}\text{Th}$ , using updated and previous biokinetic models for thorium ...	C-22
D.1 Reported half-times for the short-term retention component for tritium taken in mainly as HTO by adult humans .....	D-11
D.2 Reported biological half-times for cesium in adult male humans .....	D-15
D.3 Estimated effects of age on effective dose for photons uniformly distributed in angle .....	D-23
D.4 Uncertainty distributions assigned to the DDREF in recent reports .....	D-28
D.5 Comparison of predictions of cancer mortality based on simplistic estimate with risk coefficients for intake of radionuclides in tap water .....	D-35
E.1 Comparison of gender-specific age-distributions in 1996 U.S. population with hypothetical stationary distributions based on 1989-91 U.S. life table .....	E-2

## CHAPTER 1. INTRODUCTION

Since the mid-1980s, a series of Federal guidance documents has been issued by the Environmental Protection Agency (EPA) for the purpose of providing Federal and State agencies with technical information to assist their implementation of radiation protection programs. Previous reports have dealt with numerical factors, called "dose factors" or "dose coefficients", for estimating radiation dose due to exposure to radionuclides. The present report is intended as the first of a series of documents that will provide numerical factors, called "risk coefficients", for estimating risks to health from exposure to radionuclides. These reports will apply state-of-the-art methods and models that take into account age and gender dependence of intake, metabolism, dosimetry, radiogenic risk, and competing causes of death in estimating the risks to health from internal or external exposure to radionuclides. The present report provides tabulations of cancer risk coefficients for internal or external exposure to any of more than 800 radionuclides through various environmental media. Subsequent reports may expand the exposure pathways and health endpoints considered.

The risk coefficients developed in this report apply to an average member of the public, in the sense that estimates of risk are averaged over the age and gender distributions of a hypothetical closed "stationary" population whose survival functions and cancer mortality rates are based on recent data for the U.S. Specifically, the total mortality rates in this population are defined by the 1989-91 U.S. decennial life table (NCHS, 1997), and cancer mortality rates are defined by U.S. cancer mortality data for the same period (NCHS, 1992, 1993a, 1993b). This hypothetical population is referred to as "stationary" because the gender-specific birth rates and survival functions are assumed to remain invariant over time.

For a given radionuclide and exposure mode, both a "mortality risk coefficient" and a "morbidity risk coefficient" are provided. A mortality risk coefficient is an estimate of the risk to an average member of the U.S. population, *per unit activity inhaled or ingested for internal exposures or per unit time-integrated activity concentration in air or soil for external exposures*, of dying from cancer as a result of intake of the radionuclide or external exposure to its emitted radiations. A morbidity risk coefficient is a comparable estimate of the average total risk of experiencing a radiogenic cancer, whether or not the cancer is fatal. The term "risk coefficient" with no modifier should be interpreted throughout this report as "mortality or morbidity risk coefficient".

It is a common practice to estimate the cancer risk from intake of a radionuclide or external exposure to its emitted radiations as the simple product of a "probability coefficient" and an estimated "effective dose" to a typical adult (see the Glossary for definitions). For example, a



"nominal cancer fatality probability coefficient" of  $0.05 \text{ Sv}^{-1}$  is given in ICRP Publication 60 (1991) for all cancer types combined. This value is referred to as nominal because of the uncertainties inherent in radiation risk estimates and because it is based on an idealized population receiving a uniform dose over the whole body. It is pointed out by the ICRP (1991) that such a probability coefficient may be a less accurate estimator in situations where the distribution of dose is nonuniform. There are also other situations in which the product of a probability coefficient and the effective dose may not accurately represent the risk implied by current biokinetic, dosimetric, and radiation risk models. For example, such a product may understate the implied risk for intakes of radionuclides for which there is an apparently multiplicative effect during childhood of elevated organ doses and elevated risk per unit dose. Such a product may overstate the risk implied by current models in the case of intake of a long-lived, tenaciously retained radionuclide because much of the dose may be received during late adulthood when there is a relatively high likelihood of dying from a competing cause before a radiogenic cancer can be expressed. Finally, the weighting factors commonly used to calculate effective dose do not reflect the most up-to-date knowledge of the distribution of risk among the organs and tissues of the body.

In contrast to risk estimates based on the product of a probability coefficient and effective dose (for intake by the adult), the risk coefficients tabulated in this document take into account the age dependence of the biological behavior and internal dosimetry of ingested or inhaled radionuclides. Also, compared with risk estimates based on effective dose, the risk coefficients in this document characterize more precisely the implications of age and gender dependence in radiogenic risk models, U.S. cancer mortality rates, and competing risks from non-radiogenic causes of death in the U.S. Finally, these risk coefficients take into account the age and gender dependence in the usage of contaminated environmental media, which is generally not considered in risk estimates based on the simple product of a nominal probability coefficient and an estimated effective dose.

### **Radionuclides and exposure scenarios addressed**

Risk coefficients are provided for the following modes of exposure to a given radionuclide: inhalation of air, ingestion of food, ingestion of tap water, external exposure from submersion in air, external exposure from the ground surface, and external exposure from soil contaminated to an infinite depth.

With a few exceptions described in Chapter 6, the radionuclides addressed in the external exposure scenarios are the same as those considered in Federal Guidance Report No. 12 (EPA,

Table 2.2a, continued

Nuclide	T <sub>1/2</sub>	Chain P D		f <sub>1</sub>	Tap Water Intakes		Dietary Intakes	
					Mortality (Bq <sup>-1</sup> )	Morbidity (Bq <sup>-1</sup> )	Mortality (Bq <sup>-1</sup> )	Morbidity (Bq <sup>-1</sup> )
Francium								
Fr-222	14.4 m	Y	Y	1.0	2.85E-11	4.00E-11	3.88E-11	5.47E-11
Fr-223	21.8 m	Y	Y	1.0	1.32E-10	1.97E-10	1.80E-10	2.71E-10
Radium								
Ra-223	11.434 d	Y	Y	0.2	4.00E-09	6.44E-09	5.63E-09	9.15E-09
Ra-224	3.66 d	Y	Y	0.2	2.74E-09	4.50E-09	3.88E-09	6.42E-09
Ra-225	14.8 d	Y	Y	0.2	2.20E-09	3.09E-09	2.93E-09	4.15E-09
Ra-226 <sup>a</sup>	1600 y	Y	Y	0.2	7.17E-09	1.04E-08	9.56E-09	1.39E-08
Ra-227	42.2 m	Y	-	0.2	2.15E-12	2.85E-12	2.96E-12	3.95E-12
Ra-228	5.75 y	Y	Y	0.2	2.00E-08	2.81E-08	2.74E-08	3.86E-08
Actinium								
Ac-224	2.9 h	Y	Y	0.0005	9.02E-11	1.51E-10	1.28E-10	2.17E-10
Ac-225	10.0 d	Y	Y	0.0005	2.94E-09	5.10E-09	4.20E-09	7.33E-09
Ac-226	29 h	Y	Y	0.0005	1.03E-09	1.87E-09	1.52E-09	2.74E-09
Ac-227	21.773 y	Y	Y	0.0005	4.43E-09	5.43E-09	5.34E-09	6.63E-09
Ac-228	6.13 h	Y	Y	0.0005	3.10E-11	5.38E-11	4.49E-11	7.82E-11
Thorium								
Th-226	30.9 m	Y	Y	0.0005	1.45E-11	1.80E-11	2.02E-11	2.52E-11
Th-227	18.718 d	Y	Y	0.0005	7.21E-10	1.28E-09	1.05E-09	1.87E-09
Th-228	1.9131 y	Y	Y	0.0005	1.82E-09	2.90E-09	2.46E-09	3.99E-09
Th-229	7340 y	Y	Y	0.0005	4.39E-09	6.05E-09	5.65E-09	7.85E-09
Th-230	7.7E4 y	Y	Y	0.0005	1.67E-09	2.46E-09	2.16E-09	3.22E-09
Th-231	25.52 h	Y	Y	0.0005	3.31E-11	5.96E-11	4.86E-11	8.75E-11
Th-232 <sup>a</sup>	1.41E10 y	Y	Y	0.0005	1.87E-09	2.73E-09	2.45E-09	3.60E-09
Th-234	24.10 d	Y	Y	0.0005	3.46E-10	6.25E-10	5.07E-10	9.18E-10
Protactinium								
Pa-227	38.3 m	Y	-	0.0005	2.00E-11	2.62E-11	2.81E-11	3.70E-11
Pa-228	22 h	Y	-	0.0005	5.53E-11	9.72E-11	7.96E-11	1.40E-10
Pa-230	17.4 d	Y	-	0.0005	5.79E-11	1.02E-10	8.29E-11	1.46E-10
Pa-231	3.276E4 y	Y	Y	0.0005	3.30E-09	4.67E-09	4.29E-09	6.11E-09
Pa-232	1.31 d	Y	-	0.0005	5.32E-11	9.41E-11	7.68E-11	1.36E-10
Pa-233	27.0 d	Y	Y	0.0005	8.34E-11	1.50E-10	1.22E-10	2.20E-10
Pa-234	6.70 h	Y	Y	0.0005	4.00E-11	6.93E-11	5.77E-11	1.00E-10
Uranium								
U-230	20.8 d	Y	Y	0.02	3.24E-09	5.65E-09	4.59E-09	8.05E-09
U-231	4.2 d	Y	Y	0.02	2.63E-11	4.73E-11	3.84E-11	6.91E-11
U-232	72 y	Y	Y	0.02	5.52E-09	7.88E-09	7.22E-09	1.04E-08
U-233	1.585E5 y	Y	Y	0.02	1.26E-09	1.94E-09	1.69E-09	2.62E-09
U-234 <sup>a</sup>	2.445E5 y	Y	Y	0.02	1.24E-09	1.91E-09	1.66E-09	2.58E-09
U-235	703.8E6 y	Y	Y	0.02	1.21E-09	1.88E-09	1.62E-09	2.55E-09
U-236	2.3415E7 y	Y	Y	0.02	1.17E-09	1.81E-09	1.57E-09	2.44E-09
U-237	6.75 d	Y	Y	0.02	7.31E-11	1.32E-10	1.07E-10	1.93E-10

Table 2.2a, continued

Nuclide	T <sub>1/2</sub>	Chain P D		f <sub>1</sub>	Tap Water Intakes		Dietary Intakes	
					Mortality (Bq <sup>-1</sup> )	Morbidity (Bq <sup>-1</sup> )	Mortality (Bq <sup>-1</sup> )	Morbidity (Bq <sup>-1</sup> )
Uranium, continued								
U-238	4.468E9 y	Y	Y	0.02	1.13E-09	1.73E-09	1.51E-09	2.34E-09
U-239	23.54 m	Y	-	0.02	1.40E-12	2.00E-12	1.98E-12	2.86E-12
U-240	14.1 h	Y	Y	0.02	1.06E-10	1.90E-10	1.55E-10	2.79E-10
Neptunium								
Np-232	14.7 m	Y	-	0.0005	4.21E-13	5.33E-13	5.73E-13	7.29E-13
Np-233	36.2 m	Y	Y	0.0005	1.01E-13	1.36E-13	1.39E-13	1.89E-13
Np-234	4.4 d	Y	Y	0.0005	5.27E-11	9.19E-11	7.49E-11	1.31E-10
Np-235	396.1 d	Y	Y	0.0005	5.18E-12	9.34E-12	7.59E-12	1.37E-11
Np-236a	115E3 y	Y	-	0.0005	1.78E-10	2.83E-10	2.42E-10	3.90E-10
Np-236b	22.5 h	Y	Y	0.0005	1.68E-11	3.01E-11	2.46E-11	4.41E-11
Np-237	2.14E6 y	Y	Y	0.0005	1.10E-09	1.67E-09	1.44E-09	2.24E-09
Np-238	2.117 d	Y	Y	0.0005	8.14E-11	1.46E-10	1.19E-10	2.13E-10
Np-239	2.355 d	Y	Y	0.0005	7.70E-11	1.39E-10	1.13E-10	2.03E-10
Np-240	65 m	Y	-	0.0005	4.18E-12	6.04E-12	5.86E-12	8.55E-12
Plutonium								
Pu-234	8.8 h	Y	Y	0.0005	1.31E-11	2.32E-11	1.90E-11	3.37E-11
Pu-235	25.3 m	Y	-	0.0005	9.16E-14	1.18E-13	1.26E-13	1.63E-13
Pu-236	2.851 y	Y	Y	0.0005	1.44E-09	2.02E-09	1.87E-09	2.68E-09
Pu-237	45.3 d	Y	Y	0.0005	8.73E-12	1.56E-11	1.27E-11	2.27E-11
Pu-238	87.74 y	Y	Y	0.0005	2.75E-09	3.55E-09	3.50E-09	4.58E-09
Pu-239 <sup>a</sup>	24065 y	Y	Y	0.0005	2.85E-09	3.64E-09	3.63E-09	4.70E-09
Pu-240	6537 y	Y	Y	0.0005	2.85E-09	3.65E-09	3.63E-09	4.71E-09
Pu-241	14.4 y	Y	Y	0.0005	3.94E-11	4.77E-11	5.07E-11	6.17E-11
Pu-242	3.763E5 y	Y	Y	0.0005	2.71E-09	3.46E-09	3.45E-09	4.47E-09
Pu-243	4.956 h	Y	Y	0.0005	7.33E-12	1.28E-11	1.07E-11	1.87E-11
Pu-245	10.5 h	Y	-	0.0005	6.75E-11	1.21E-10	9.87E-11	1.77E-10
Pu-246	10.85 d	Y	Y	0.0005	2.60E-10	4.68E-10	3.80E-10	6.84E-10
Americium								
Am-237	73.0 m	Y	-	0.0005	9.26E-13	1.37E-12	1.30E-12	1.94E-12
Am-238	98 m	Y	Y	0.0005	1.70E-12	2.60E-12	2.36E-12	3.64E-12
Am-239	11.9 h	Y	-	0.0005	2.10E-11	3.73E-11	3.06E-11	5.44E-11
Am-240	50.8 h	Y	-	0.0005	4.00E-11	6.99E-11	5.71E-11	1.00E-10
Am-241	432.2 y	Y	Y	0.0005	2.01E-09	2.81E-09	2.56E-09	3.63E-09
Am-242	16.02 h	Y	Y	0.0005	2.71E-11	4.83E-11	3.96E-11	7.08E-11
Am-242m	152 y	Y	-	0.0005	1.47E-09	1.91E-09	1.80E-09	2.37E-09
Am-243	7380 y	Y	Y	0.0005	2.00E-09	2.79E-09	2.54E-09	3.61E-09
Am-244	10.1 h	Y	-	0.0005	3.86E-11	6.80E-11	5.60E-11	9.89E-11
Am-244m	26 m	Y	-	0.0005	1.14E-12	1.38E-12	1.58E-12	1.92E-12
Am-245	2.05 h	Y	Y	0.0005	3.73E-12	6.01E-12	5.37E-12	8.71E-12
Am-246	39 m	Y	-	0.0005	2.54E-12	3.33E-12	3.53E-12	4.67E-12
Am-246m	25.0 m	Y	Y	0.0005	1.43E-12	1.78E-12	1.97E-12	2.46E-12

**Table 7.1. Revised mortality risk model coefficients<sup>a,b</sup> for cancers other than leukemia, based on the EPA radiation risk methodology (EPA, 1994).**

Cancer type	Risk model type <sup>c</sup>	Age group ( $x_a$ )				
		0-9 y	10-19 y	20-29 y	30-39 y	40+ y
Male:						
Esophagus	R	0.2877	0.2877	0.2877	0.2877	0.2877
Stomach	R	1.223	1.972	2.044	0.3024	0.2745
Colon	R	2.290	2.290	0.2787	0.4395	0.08881
Liver	R	0.9877	0.9877	0.9877	0.9877	0.9877
Lung	R	0.4480	0.4480	0.0435	0.1315	0.1680
Bone	A	0.09387	0.09387	0.09387	0.09387	0.09387
Skin	A	0.06597	0.06597	0.06597	0.06597	0.06597
Breast	R	0.0	0.0	0.0	0.0	0.0
Ovary	R	0.0	0.0	0.0	0.0	0.0
Bladder	R	1.037	1.037	1.037	1.037	1.037
Kidney	R	0.2938	0.2938	0.2938	0.2938	0.2938
Thyroid	A	0.1667	0.1667	0.08333	0.08333	0.08333
Residual	R	0.5349	0.5349	0.6093	0.2114	0.04071
Female:						
Esophagus	R	1.805	1.805	1.805	1.805	1.805
Stomach	R	3.581	4.585	4.552	0.6309	0.5424
Colon	R	3.265	3.265	0.6183	0.8921	0.1921
Liver	R	0.9877	0.9877	0.9877	0.9877	0.9877
Lung	R	1.359	1.359	0.1620	0.4396	0.6047
Bone	A	0.09387	0.09387	0.09387	0.09387	0.09387
Skin	A	0.06597	0.06597	0.06597	0.06597	0.06597
Breast	R	0.7000	0.7000	0.3000	0.3000	0.1000
Ovary	R	0.7185	0.7185	0.7185	0.7185	0.7185
Bladder	R	1.049	1.049	1.049	1.049	1.049
Kidney	R	0.2938	0.2938	0.2938	0.2938	0.2938
Thyroid	A	0.3333	0.3333	0.1667	0.1667	0.1667
Residual	R	1.122	1.122	0.8854	0.3592	0.1175

<sup>a</sup>The tabulated risk model coefficients are the precise values derived from the epidemiological data and used in the calculations. The use of four significant digits should not be interpreted as indicating a low level of uncertainty in the risk model coefficients.

<sup>b</sup>Age-specific risk model coefficients were used to derive composite risk coefficients representing averages over all ages. Application of these risk model coefficients to a specific age group is not recommended due to the high sampling variability in the underlying epidemiological data for some age groups.

<sup>c</sup>A indicates that an absolute risk model is used (coefficient units,  $10^{-4} \text{ Gy}^{-1} \text{ y}^{-1}$ ), and R indicates that a relative risk model is used ( $\text{Gy}^{-1}$ ).  $\alpha(x_a)$  is given for absolute risk model (Eq. 7.1) and  $\beta(x_a)$  for a relative risk model (Eq. 7.2).

**Table 7.2. Revised mortality risk model coefficients ( $\text{Gy}^{-1}$ ) for leukemia, based on the EPA radiation risk methodology (EPA, 1994).<sup>a</sup>**

Gender	Age group ( $x_e$ )				
	0-9 y	10-19 y	20-29 y	30-39 y	40+ y
Male	982.3	311.3	416.6	264.4	143.6
Female:	1176	284.9	370.0	178.8	157.1

<sup>a</sup>A relative risk model is used (coefficient units,  $\text{Gy}^{-1}$ ). Risk model coefficients for leukemia are not directly comparable to those for other types of cancer (Table 7.1) due to differences in the scales of the time-since-exposure response functions for leukemia and other cancers (see the discussion following Eq. 7.2).

by Land and Sinclair for transporting risk from one population to another. Both methods assume a constant excess relative risk coefficient beginning 10 y after an exposure and continuing throughout the rest of life for each cancer site, excluding leukemia. One method (multiplicative) assumes that the relative risk estimator is the same across populations. The other (NIH, for National Institutes of Health) assumes that the relative risk model coefficients for the target population should yield the same risks as those calculated with the additive risk model coefficients from the original population over the period of epidemiological follow-up, excluding the minimal latency period. These excess relative risk model coefficients are then used to project the risk over the remaining years of life. The data considered in deriving risk model coefficients consisted of cancers observed 10-40 y after exposure for solid tumors and 5-40 y after exposure for leukemia.

As described below, some modifications in the method of calculation of the NIH model coefficients have been made to remove inconsistencies in the derived coefficients. Some but not all of these changes were made in the EPA report on radiation risk models (EPA, 1994); therefore, some of the risk coefficients in Tables 7.1 and 7.2 differ from values given in that report.

An examination of the coefficients for the additive and multiplicative models of Land and Sinclair (1991) reveals that in several instances data for exposures of two or more age groups were combined to calculate a single risk coefficient. In such cases, a single NIH model coefficient has been calculated for use in the present report by combining the risks calculated for the corresponding groups. This was done in the EPA report (EPA, 1994) for model coefficients for lung and colon cancer for two exposure age groups (0-9 y and 10-19 y), and the same principle has been extended in the present report to the coefficients for esophagus, ovary, and bladder cancer. For these three sites, the age-group-specific additive coefficients of Land and Sinclair were based on a single-coefficient multiplicative risk model. For the present report, an NIH model excess relative

**Table 7.3. Age-averaged site-specific cancer mortality risk estimates (cancer deaths per person-Gy) from low-dose, low-LET uniform irradiation of the body.**

Site	Males	Females	Combined genders
Esophagus	$7.30 \times 10^{-4}$	$1.59 \times 10^{-3}$	$1.17 \times 10^{-3}$
Stomach	$3.25 \times 10^{-3}$	$4.86 \times 10^{-3}$	$4.07 \times 10^{-3}$
Colon	$8.38 \times 10^{-3}$	$1.24 \times 10^{-2}$	$1.04 \times 10^{-2}$
Liver	$1.84 \times 10^{-3}$	$1.17 \times 10^{-3}$	$1.50 \times 10^{-3}$
Lung	$7.71 \times 10^{-3}$	$1.19 \times 10^{-2}$	$9.88 \times 10^{-3}$
Bone	$9.40 \times 10^{-5}$	$9.60 \times 10^{-5}$	$9.50 \times 10^{-5}$
Skin	$9.51 \times 10^{-5}$	$1.05 \times 10^{-4}$	$1.00 \times 10^{-4}$
Breast	—	$9.90 \times 10^{-3}$	$5.06 \times 10^{-3}$
Ovary	—	$2.92 \times 10^{-3}$	$1.49 \times 10^{-3}$
Bladder	$3.28 \times 10^{-3}$	$1.52 \times 10^{-3}$	$2.38 \times 10^{-3}$
Kidney	$6.43 \times 10^{-4}$	$3.92 \times 10^{-4}$	$5.15 \times 10^{-4}$
Thyroid	$2.05 \times 10^{-4}$	$4.38 \times 10^{-4}$	$3.24 \times 10^{-4}$
Leukemia	$6.48 \times 10^{-3}$	$4.71 \times 10^{-3}$	$5.57 \times 10^{-3}$
Residual <sup>a</sup>	$1.35 \times 10^{-2}$	$1.63 \times 10^{-2}$	$1.49 \times 10^{-2}$
Total	$4.62 \times 10^{-2}$	$6.83 \times 10^{-2}$	$5.75 \times 10^{-2}$

<sup>a</sup>Residual is a composite of all radiogenic cancers that are not explicitly identified by site in the model.

Publication 60 (1991), except that the weights assigned to regions within the colon and lung are based on more recent recommendations in ICRP Publication 66 (1994a) and 67 (1993), respectively. The residual cancer category represents a composite of primary and secondary cancers that are not otherwise considered in the model. The three dose locations associated with these cancers (skeletal muscle, pancreas, and adrenals) were chosen to be generally representative of doses to soft tissues and are not considered to be the sites where all residual neoplasms originate.

**Table 7.6. Age-averaged site-specific cancer morbidity risk estimates (cancer cases per person-Gy) from low-dose, low-LET uniform irradiation of the body.**

Site	Male	Female	Combined genders
Esophagus	$7.69 \times 10^{-4}$	$1.68 \times 10^{-3}$	$1.23 \times 10^{-3}$
Stomach	$3.61 \times 10^{-3}$	$5.40 \times 10^{-3}$	$4.53 \times 10^{-3}$
Colon	$1.52 \times 10^{-2}$	$2.25 \times 10^{-2}$	$1.89 \times 10^{-2}$
Liver	$1.94 \times 10^{-3}$	$1.23 \times 10^{-3}$	$1.58 \times 10^{-3}$
Lung	$8.12 \times 10^{-3}$	$1.26 \times 10^{-2}$	$1.04 \times 10^{-2}$
Bone	$1.34 \times 10^{-4}$	$1.37 \times 10^{-4}$	$1.36 \times 10^{-4}$
Skin <sup>a</sup>	$9.51 \times 10^{-5}$	$1.05 \times 10^{-4}$	$1.00 \times 10^{-4}$
Breast	—	$1.98 \times 10^{-2}$	$1.01 \times 10^{-2}$
Ovary	—	$4.17 \times 10^{-3}$	$2.13 \times 10^{-3}$
Bladder	$6.55 \times 10^{-3}$	$3.04 \times 10^{-3}$	$4.76 \times 10^{-3}$
Kidney	$9.88 \times 10^{-4}$	$6.03 \times 10^{-4}$	$7.91 \times 10^{-4}$
Thyroid	$2.05 \times 10^{-3}$	$4.38 \times 10^{-3}$	$3.24 \times 10^{-3}$
Leukemia	$6.54 \times 10^{-3}$	$4.75 \times 10^{-3}$	$5.63 \times 10^{-3}$
Residual <sup>b</sup>	$1.91 \times 10^{-2}$	$2.29 \times 10^{-2}$	$2.11 \times 10^{-2}$
Total	$6.51 \times 10^{-2}$	$1.03 \times 10^{-1}$	$8.46 \times 10^{-2}$

<sup>a</sup>Skin cancer morbidity risk coefficients include fatal cancer risks only. See text.

<sup>b</sup>Residual is a composite of all radiogenic cancers that are not explicitly identified by site in the model.

averaged values for the hypothetical stationary population described in Chapter 3. The method of computation is described in a later section.

Based on the methods of this report, skin is projected to contribute most of the nonfatal cancers induced by uniform whole body irradiation. At least 83% of all skin cancers are basal cell carcinomas and the remainder are squamous cell carcinomas. Approximately 99.99% of the former and 99% of the latter are non-fatal. The morbidity estimates for skin cancer given in the present report reflect only fatal cases.